Alexander Nimri, MD
Nephrology · Phoenix, AZNPI 1467666123
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 451 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations. Among nephrology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 451 payments — averaging $47.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AstraZeneca$3K
- Travere Therapeutics, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Mallinckrodt Hospital Products Inc.$2K
- Bayer$1K
- plus $8K from 34 others
Across 4 payments — averaging $27,837 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$61K
- Vertex$51K
What the payments were for
- Food & beverage$20,69898%
- Education$5152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$1,542
- ACTHAR$917
- Kerendia$844
- LOKELMA$844
- Tavneos$834
- XARELTO$564
- ULTOMIRIS$481
- JYNARQUE$475
- FARXIGA$468
- Veltassa$463
- Velphoro$373
- TERLIVAZ$364
- CardioMEMS HF System$358
- Ozempic$244
- AVYCAZ$226
- MOUNJARO$219
- FLOWTRIEVER CATHETER, S$167
- CT THROMBECTOMY SYSTEM KIT$167
- Fabhalta$140
- (6574) Coronary Other$129
How this compares
$21,212 in reported general payments places this provider in the 95th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 160 | $150,618 |
| VelphoroSucroferric Oxyhydroxide | 17 | $60,612 |
| KerendiaFinerenone | 50 | $55,485 |
| OzempicSemaglutide | 34 | $46,318 |
| JardianceEmpagliflozin | 32 | $28,934 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $18,961 |
| Sevelamer Carbonate | 47 | $9,873 |
| LokelmaSodium Zirconium Cyclosilicate | 18 | $9,005 |
| DapagliflozinDapagliflozin Propanediol | 15 | $7,482 |
| Nifedipine ErNifedipine | 25 | $613 |
| Fluconazole | 19 | $563 |
| Bumetanide | 11 | $425 |
| Losartan Potassium | 54 | $288 |
| Metoprolol Succinate | 29 | $267 |
| Tamsulosin Hcl | 16 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $3,039 | $159,623178 claims |
| Fresenius USA Marketing, Inc.Velphoro | $695 | $60,61217 claims |
| BayerKerendia | $1,461 | $55,48550 claims |
| Novo NordiskOzempic | $631 | $46,31834 claims |
| Boehringer IngelheimJardiance | $165 | $28,93432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 nephrology providers in Arizona.
Other nephrology in Phoenix
- Samer Bani HaniPhoenix$54K
- Leslie ThomasPhoenix$22K
- Edgardo LaurelPhoenix$15K
- Sharareh SaadatPhoenix$15K
- Amar BistaPhoenix$12K
- Maher MousaPhoenix$9K
- Paul SacksPhoenix$8K
- William WeissPhoenix$8K
- Esmat MustafaPhoenix$7K
- Hui ZhaoPhoenix$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.